| Document |
Document Title |
|
WO/2024/020484A3 |
RNA molecules comprising a guide sequence portion consisting of 17-50 nucleotides and containing 17-22 nucleotides in the sequence set forth in any one of SEQ ID NOs: 1-20347, and compositions, methods, and uses thereof.
|
|
WO/2024/040081A3 |
The present disclosure describes methods of generating a transgenic cell or mouse that expresses a chimeric c-KIT protein capable of expression on mouse cells and binding to mouse stem cell factor (SCF) which can be inhibited by anti-hum...
|
|
WO/2024/055022A3 |
An HSV vector with an expression cassette encoding an immune cell engager protein under control of an EF1α promoter, ICP27 under control of a CEA promoter, ICP34.5 under control of miRNA-124/143, and ICP47 under control of a ICP27 promo...
|
|
WO/2024/097892A1 |
This disclosure relates to introducing specified endogenous amiRNA responsive to endogenous primary-miRNAs. This invention allows the degradation of amiRNAs in specific tissues, while allowing amiRNA to silence gene expression in other t...
|
|
WO/2024/097243A1 |
Disclosed herein are yeast strains and derivatives thereof, as well as compositions comprising the yeast strains for use in ethanol manufacture. The disclosure also relates to processes for producing ethanol from biomass using the yeast ...
|
|
WO/2024/097418A2 |
Provided herein are gene activation and interference targets for exhaustion/dysfunction-resistant t cell products and uses thereof.
|
|
WO/2024/097829A1 |
Described herein are compositions for inhibiting a protease or coagulation target comprising a nucleic acid aptamer covalently linked to a small molecule inhibitor and methods for using the same to inhibit coagulation. Also provided are ...
|
|
WO/2024/094793A1 |
The present invention relates to the purification of linear DNA products, which may have nuclease-resistance. The linear DNA products may be double-stranded or single stranded. In addition, the present invention relates to purified linea...
|
|
WO/2024/097732A2 |
The present invention provides nucleic acid-loaded virus-like particles (VLPs) that can be produced in plants and are designed to deliver a nucleic acid into plant cells. Also provided are compositions comprising the nucleic acid-loaded ...
|
|
WO/2024/093790A1 |
The present application relates to the field of biotechnology, and in particular, to a stable and high-yield targeted integration cell, a method for preparing same, and use thereof. Compared with conventional techniques, the present appl...
|
|
WO/2024/094159A1 |
Provided in the present application are a single domain antibody targeting the ROR1 protein as well as a chimeric antigen receptor (CAR) and CAR-T cell comprising the single domain antibody. Also provided are uses of the single domain an...
|
|
WO/2024/092330A1 |
The present invention relates to nucleotide sequences that encode new truncated chimeric insecticidal proteins that exhibit inhibitory activity on lepidopterans. Particular embodiments provide compositions and plants, parts of parts, and...
|
|
WO/2024/097674A2 |
Described are short interfering nucleic acid (siNA) molecules comprising modified nucleotides, compositions, and methods and uses thereof.
|
|
WO/2024/096124A1 |
The present disclosure provides a microorganism that inhibits oligomer formation of sgA. More specifically, the present disclosure provides a microorganism wherein at least one gene among the curli pili operon gene group, sigma factor ge...
|
|
WO/2024/092388A1 |
The present invention provides a nucleic acid loading reagent and a method for detecting the nucleic acid adsorption capacity of a sequencing chip using same. The method comprises at least one of the following conditions: (i) the nucleic...
|
|
WO/2024/094017A1 |
Provided are a GPC3 bispecific antigen binding molecule or an antigen binding fragment thereof, a derivative containing the bispecific antigen binding molecule or the antigen binding fragment thereof, and a pharmaceutical composition. In...
|
|
WO/2023/230551A3 |
Some embodiments of the methods and compositions provided herein relate to obtaining long read information from short reads of a target nucleic acid. Some embodiments include steps to selectively generate, mark, and amplify long nucleic ...
|
|
WO/2024/093042A1 |
Provided are an anti-BSA rabbit monoclonal antibody and use thereof, which belong to the technical field of antibodies. The anti-BSA rabbit monoclonal antibody or an antigen-binding portion thereof specifically binds to BSA. The monoclon...
|
|
WO/2024/093915A1 |
Provided are a protein comprising an amino acid sequence capable of binding to a substrate GPRP peptide fragment, a fibrinogen like protein 1 (FGL1) comprising the amino acid sequence, and a fibrinogen domain (FD) thereof, and an individ...
|
|
WO/2024/044537A3 |
Novel pesticidal polypeptides that are active against Coleopteran pests are disclosed. Nucleic acid molecules encoding the novel insecticidal proteins are also provided. The nucleotide sequences encoding the pesticidal polypeptides can b...
|
|
WO/2024/064895A3 |
The present disclosure relates to adeno-associated virus (AAV)-mediated delivery of nucleic acids for treating neuromuscular disorders, e.g., X-linked myotubular myopathy (XLMTM), in patients in need thereof. The AAV vectors of the discl...
|
|
WO/2024/098037A1 |
The present disclosure provides chimeric receptor constructs comprising a CD3e extracellular domain and engineered NK and T cells expressing such receptors and methods of making and using same for the treatment of cancer and other diseas...
|
|
WO/2024/036165A3 |
The adrenal cortex is the major endocrine hub for steroid hormone production, and thus regulates a wide variety of critical physiologic functions vital to human life, including immune and stress responses, sexual maturation, and electrol...
|
|
WO/2024/094044A1 |
The present disclosure relates to an optimized PAH gene and an expression cassette and use thereof. Specifically, a polynucleotide molecule encoding PAH protein is disclosed. By means of using the polynucleotide molecule, expression cass...
|
|
WO/2024/097603A2 |
Provided herein are methods of producing heterozygous edited animals by injecting zygotes with low amounts of ribonucleoprotein (RNP) complex. The data cited herein show that more heterozygous animals are obtained from zygotes injected w...
|
|
WO/2024/096545A1 |
The present application relates to a microorganism producing purine nucleotides and a method for producing purine nucleotides using same.
|
|
WO/2024/098036A1 |
The subject matter described here relates to anti -PAG antibodies. The subject matter described here also provides a pharmaceutical composition of, or a kit for generating an anti-PAG antibody; a method of making an anti-PAG antibody; a ...
|
|
WO/2024/050514A3 |
A device, method, and kit are disclosed for use in detecting a target analyte in a sample. The device includes a region having a first zone, into which the sample can be delivered, and a second zone in fluid communication with the first ...
|
|
WO/2024/098042A2 |
Provided herein is a growth selection platform for noncanonical cofactor oxidizing enzymes, the noncanonical cofactor oxidizing enzymes identified thereof, and applications thereof.
|
|
WO/2024/096120A1 |
The present disclosure relates to improving the colonization properties of a bacterial preparation in a host. Specifically, the present disclosure relates to a microorganism wherein at least one gene is modified, said modification improv...
|
|
WO/2024/096038A1 |
The present invention addresses the problem of providing a method for producing active HGF in an industrially advantageous manner, by expressing HGF α chain and HGF β chain in the same host cell. The present disclosure provides a met...
|
|
WO/2024/092713A1 |
Disclosed in the present invention is an MMLV reverse transcriptase mutant. Compared with the amino acid sequence of wild-type MMLV reverse transcriptase, the MMLV reverse transcriptase mutant provided in the present invention has mutati...
|
|
WO/2024/073362A3 |
Aspects of the present disclosure are directed to liquid and substantially solid film compositions for storage, transport, and administration of agents, including nucleic acids, without the use of ultralow temperatures. Provided are comp...
|
|
WO/2024/093147A1 |
The present invention relates to an antibody specifically binding to the v5 exon of human CD44 or a fragment thereof. The present invention also relates to a chimeric antigen receptor molecule comprising the antibody or the fragment ther...
|
|
WO/2024/097916A2 |
The present disclosure provides compositions (e.g., pharmaceutical compositions) and methods for treating conditions associated with aberrant expression of KRT17, including psoriasis and certain malignancies. The compositions comprise an...
|
|
WO/2024/098031A1 |
Described herein are methods of modulating ABCB11 gene transcription using antisense oligonucleotides (ASOs) targeting regulatory RNAs, such as promoter-associated RNAs and enhancer RNAs. These methods are useful for increasing the expre...
|
|
WO/2024/077089A3 |
The disclosure relates generally to methods of producing recombinant viral vectors with reduced immunogenicity.
|
|
WO/2024/095599A1 |
Provided is a method for producing glomus cell-like cells, the method including: (a) a step for inducing differentiation of pluripotent stem cells into autonomic progenitor cells; and (b) a step for culturing the autonomic progenitor cel...
|
|
WO/2024/094002A1 |
The present invention relates to a fructose diphosphate optical probe. Specifically, provided in the present invention is a fructose diphosphate optical probe, which comprises a fructose-1,6-diphosphate sensitive polypeptide and an optic...
|
|
WO/2023/177526A9 |
The disclosure provides nucleic acid molecules (comprising expression cassettes), plasmids, protein molecules, cells (comprising nucleic acid molecules), and recombinant expression systems for producing recombinant cascade reagents for t...
|
|
WO/2024/073407A3 |
The present disclosure provides recombinant viruses comprising recombinant target surface molecules. The present disclosure further provides pharmaceutical compositions comprising the recombinant viruses and methods of using the viruses ...
|
|
WO/2023/205510A3 |
The invention relates to compositions and methods for determining risk of developing myeloproliferative disorders. In certain embodiments, the invention includes screening for mutations in the genes JAK2, MPL (thrombopoietin receptor), a...
|
|
WO/2024/096506A1 |
The present invention relates to a method for preparing a high-concentration liquid medium having reduced osmotic pressure, and a method for producing a protein of interest by using the medium. When the high-concentration liquid medium i...
|
|
WO/2024/097821A1 |
The present disclosure provides a Nucleotide-Based Enhancement Agent being a compound or a pharmaceutically acceptable salt thereof, comprising from 2 to 30 nucleotides, wherein each nucleotide independently is of Formula (I) or (II): (I...
|
|
WO/2024/093962A1 |
Provided is use of a compact editing tool EbCas12a in gene editing. The EbCas12a has an amino acid sequence set forth in SED ID NO. 1 or 2.
|
|
WO/2024/092769A1 |
Provided is a fusion polypeptide comprising a carrier protein and a polypeptide of interest, wherein the polypeptide of interest is fused to a terminus of the carrier protein or inserted into the carrier protein, and wherein the carrier ...
|
|
WO/2024/092768A1 |
The present invention relates to a thermostable reverse transcriptase and use thereof. The thermostable reverse transcriptase has at least one of mutation positions L333, P65, Q68, P127, P175, E176, G178, G331, T332, F334, and G105, wher...
|
|
WO/2024/094578A1 |
The present invention is directed to seedless fruit producing melon. The present invention also comprises methods for production of said plants and methods for producing seedless melon. Plants and plant parts of the invention comprise at...
|
|
WO/2024/095283A1 |
The present invention discloses a recombinant DNA encoding a protein having an amino acid sequence as set forth in SEQ ID NO: 2, or SEQ ID NO: 4. The present invention further discloses a recombinant vector comprising the recombinant DNA...
|
|
WO/2024/098076A1 |
Aspects of the present disclosure relate generally to methods, compositions, and kits for conjugating cells with magnetic beads. Aspects of the present disclosure also include methods, compositions, and kits for using magnetic bead conju...
|
